Peretinoin (Standard)

Peretinoin (Standard) is the analytical standard of Peretinoin. This product is intended for research and analytical applications. Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR) . Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1[1]. Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression[2]. Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM[3].

Product Specifications

CAS Number

[81485-25-8]

Product Name Alternative

NIK333 (Standard)

UNSPSC

12352211

Target

Autophagy; HCV; RAR/RXR; Reference Standards; SphK

Related Pathways

Anti-infection; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Infection

Smiles

C/C(C)=C/CC/C(C)=C/CC/C(C)=C/C=C/C(C)=C/C(O)=O

Molecular Formula

C20H30O2

Molecular Weight

302.45

References & Citations

[1]Funaki M, et al. Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep. 2017 Dec 5;7 (1) :16978.|[2]Okada H, et al. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet. Oncotarget. 2017 Jun 20;8 (25) :39978-39993.|[3]Honda M, et al. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191.